Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 2004 Oct;24(5):695–704. doi: 10.1023/B:CEMN.0000036406.24391.5a

Tacrolimus-Induced Neurotoxicity and Nephrotoxicity Is Ameliorated by Administration in the Dark Phase in Rats

Atsushi Yamauchi 1, Ryozo Oishi 2, Yasufumi Kataoka 1
PMCID: PMC11529933  PMID: 15485139

Abstract

1. Tacrolimus, a potent immunosuppressant, induces impaired renal function and neurological complications. We investigated the influence of dosing time on the neurotoxicity, nephrotoxicity, and immunosuppressive effect of tacrolimus in rats.

2. The repeated injection of tacrolimus in the light phase (8:00) produced a significantly greater increase than that in the dark phase (20:00) in the duration of harmine-induced tremors and in the blood urea nitrogen (BUN) concentration in rats. An immunosuppressive effect of tacrolimus on the xenotransplantation of mouse-to-rat skin grafts was apparent in the dark phase but not in the light phase.

3. The dosing time-dependent pharmacokinetic results were not observed when tacrolimus concentrations in rat whole blood were measured after a single or repeated injection in the light or dark phase.

4. These findings suggest that treatment in the active phase of the diurnal cycle ameliorates neurotoxicity and nephrotoxicity while maintaining the immunosuppressive effect of tacrolimus. The present findings have important implications for therapeutic approaches to avoid tacrolimus-induced neurotoxicity and nephrotoxicity.

Keywords: tacrolimus, neurotoxicity, nephrotoxicity, circadian rhythm, rats

REFERENCES

  1. Bobadilla, N. A., Gamba, G., Tapia, E., Garcia-Torres, R., Bolio, A., Ĺopez-Zetina, P., and Herrera-Acosta, J. (1998). Role of NO in cyclosporin nephrotoxicity: Effects of chronic NO inhibition and NO synthases gene expression. Am. J. Physiol.274:F791–F798. [DOI] [PubMed] [Google Scholar]
  2. Born, J., Lange, T., Hansen, K., Mölle, M., and Fehm, H. L. (1997). Effects of sleep and circadian rhythm on human circulating immune cells. J. Immunol.158:4454–4464. [PubMed] [Google Scholar]
  3. Brandenberger, G., Follenius, M., Goichot, B., Saini, J., Spiegel, K., Ehrhart, J., and Simon, C. (1994). Twenty-four-hour profiles of plasma renin activity in relation to the sleep-wake cycle. J. Hypartens.12:277–283. [PubMed] [Google Scholar]
  4. Cardinali, D. P., and Golombek, D. A. (1998). The rhythmic GABAergic system. Neurochem. Res.23:607–614. [DOI] [PubMed] [Google Scholar]
  5. Cavallini, M., Magnus, G., Halberg, F., Tao, L., Field, M. Y., Sibley, R., Najarian, J. S., and Sutherland, D. E. R. (1983). Benefit from circadian timing of cyclosporine revealed by delay of rejection of murine heart allograft. Transplant. Proc.15(Suppl. 1):2960–2966. [Google Scholar]
  6. EuropeanFK506Multicentre Liver Study Group. (1994). Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet.344:423–428. [PubMed] [Google Scholar]
  7. Fujimura, A., and Ebihara, A. (1994). Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK506). Life Sci.55:485–490. [DOI] [PubMed] [Google Scholar]
  8. Fujimura, A., Shiga, T., Ohashi, K., and Ebihara, A. (1993). Chronopharmacokinetic study of a new immunosuppressive agent, FK506, in mice. Jpn. J. Pharmacol.61:137–139. [DOI] [PubMed] [Google Scholar]
  9. Fujisaki, Y., Yamauchi, A., Dohgu, S., Sunada, K., Yamaguchi, C., Oishi, R., and Kataoka, Y. (2002). Cyclosporine A-increased nitric oxide production in the rat dorsal hippocampus mediates convulsions. Life Sci.72:549–556. [DOI] [PubMed] [Google Scholar]
  10. Hutson, P. H., Sarna, G. S., and Curzon, G. (1984). Determination of daily variations of brain 5-hydroxytryptamine and dopamine turnovers and of the clearance of their acidic metabolites in conscious rats by repeated sampling of cerebrospinal fluid. J. Neurochem.43:291–293. [DOI] [PubMed] [Google Scholar]
  11. Hwang, Y. S., Hsieh, T. J., Lee, Y. J., and Tsai, J. H. (1998). Circadian rhythm of urinary endothelin-1 excretion in mild hypertensive patients. Am. J. Hypertens.11:1344–1351. [DOI] [PubMed] [Google Scholar]
  12. Ikesue, H., Kataoka, Y., Kawachi, R., Dohgu, S., Shuto, H., and Oishi, R. (2000). Cyclosporine enhances a1-adrenoceptor-mediated nitric oxide production in C6 glioma cells. Eur. J. Pharmacol.407:221–226. [DOI] [PubMed] [Google Scholar]
  13. Isram, M., Burke, J. F., Jr., McGowan, T. A., Zhu, Y., Dunn, S. R., McCue, P., Kanalas, J., and Sharma, K. (2001). Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int.59:498–506. [DOI] [PubMed] [Google Scholar]
  14. Kawanishi, K., Hashimoto, Y., Fujiwara, M., Kataoka, Y., and Ueki, S. (1981). Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice. J. Pharm.Dyn.4:520–527. [DOI] [PubMed] [Google Scholar]
  15. Kupferman, J. C., Beaudoin, R., Carr, R., Hay, D., Casellas, D., Kaskel, F. J., and Moore, L. C. (1994). Activation of the renal renin-angiotensin system by cyclosporineAand FK 506 in the rat. Transplant. Proc.26:2891–2893. [PubMed] [Google Scholar]
  16. Lanese, D. M., and Conger J. D. (1993). Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles J. Clin. Invest.91:2144–2149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lanese, D. M., Falk, S. A., and Conger J. D. (1994). Sequential agonist activation and site-specificmediation of acute cyclosporine constriction in rat renal arterioles. Transplantation58:1371–1378. [PubMed] [Google Scholar]
  18. Levi, F., Zidani, R., and Misset, J. L. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet350:681–686. [DOI] [PubMed] [Google Scholar]
  19. Liu, J. (1993). FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today14:290–295. [DOI] [PubMed] [Google Scholar]
  20. Min, D. I., Chen, H. Y., Fabrega, A., Ukah, F. O., Wu, Y. M., Corwin, C., Ashton, M. K., and Martin, M. (1996). Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation62:1190–1192. [DOI] [PubMed] [Google Scholar]
  21. Ohdo, S., Koyanagi, S., Suyama, H., Higuchi, S., and Aramaki, H. (2001). Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med.7:356–360. [DOI] [PubMed] [Google Scholar]
  22. Palm, S., Postler, E., Hinrichsen, H., Maier, H., Zabel, P., and Kirch,W. (1996). Twenty-four-hour analysis of lymphocyte subpopulations and cytokines in healthy subjects. Chronobiol. Int.13:423–434. [DOI] [PubMed] [Google Scholar]
  23. Satoh, S., Tada, H., Tachiki, Y., Tsuchiya, N., Shimoda, N., Akao, T., Sato, K., Habuchi, T., Suzuki, T., and Kato, T. (2001). Chrono and clinical pharmacokietic study of tacrolimus in continuous intravenous administration. Int. J. Urol.8:353–358 [DOI] [PubMed] [Google Scholar]
  24. Shapira, O. M., Rene, H., Lider,O., Pfeffermann, R. A., Shemin, R. J., and Cohen, I. R. (1999). Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. J. Surg. Res.85:83–87. [DOI] [PubMed] [Google Scholar]
  25. Shuto, H., Kataoka, Y., Fujisaki, K., Nakao, T., Sueyasu, M., Miura, I., Watanabe, Y., Fujiwara, M., and Oishi, R. (1999). Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci.65:879–887. [DOI] [PubMed] [Google Scholar]
  26. Shuto, H., Kataoka, Y., Kanaya, A., Matsunaga, K., Sueyasu, M., and Oishi, R. (1998). Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice. Eur. J. Pharmacol.341:33–37. [DOI] [PubMed] [Google Scholar]
  27. Snyder, S. H., Sabatini, D. M., Lai, M. M., Steinet, J. P., Hamilton, G. S., and Suzdak, P. D. (1998). Neuronal actions of immunophilin ligands. Trends Pharmacol. Sci.19:{pp21-26}. [DOI] [PubMed] [Google Scholar]
  28. Steiner, J. P., Dawson, T. M., Fotuhi, M., and Snyder, S. H. (1996). Immunophilin regulation of neurotransmitter release. Mol. Med.2:325–333. [PMC free article] [PubMed] [Google Scholar]
  29. The U.S. Multicenter FK506 Liver Study Group. (1994). A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med.331:1110–1115. [DOI] [PubMed] [Google Scholar]
  30. Tominaga, K., Yamauchi, A., Shuto, H., Niizeki, M., Makino, K., Oishi, R., and Kataoka, Y. (2001). Ovariectomy aggravates convulsions and hippocampal ?-aminobutyric acid inhibition induced by cyclosporin A in rats. Eur. J. Pharmacol.430:243–249. [DOI] [PubMed] [Google Scholar]
  31. Uchida, H., Kobayashi, E., Ogino, Y., Mizuta, K., To, H., Okabe, R., Hashizume, K., and Fujimura, A. (1999). Chronopharmacology of tacrolimus in rats: Toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. Transplant. Proc.31:2751–2753. [DOI] [PubMed] [Google Scholar]
  32. Wiederrecht, G., Lam, E., Hung, S., Martin, M., and Sigal, N. (2000). The mechanism of action of FK-506 and cyclosporin A. Ann. N. Y. Acad. Sci.696:9–19. [DOI] [PubMed] [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES